Healthcare -
Biotechnology - NASDAQ - US
$ 1.48
-10.8 %
$ 4.09 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart PALI
FINANCIALS
Balance Sheet
Palisade Bio, Inc.
| Current Assets | 13.3 M |
| Cash & Short-Term Investments | 12.4 M |
| Receivables | 148 K |
| Other Current Assets | 748 K |
| Non-Current Assets | 724 K |
| Long-Term Investments | 0 |
| PP&E | 208 K |
| Other Non-Current Assets | 516 K |
| Current Liabilities | 2.59 M |
| Accounts Payable | 698 K |
| Short-Term Debt | 279 K |
| Other Current Liabilities | 1.61 M |
| Non-Current Liabilities | 153 K |
| Long-Term Debt | 90 K |
| Other Non-Current Liabilities | 63 K |
EFFICIENCY
Earnings Waterfall
Palisade Bio, Inc.
| Revenue | 250 K |
| Cost Of Revenue | 0 |
| Gross Profit | 250 K |
| Operating Expenses | 13.3 M |
| Operating Income | -13.1 M |
| Other Expenses | -770 K |
| Net Income | -12.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Palisade Bio, Inc.
| Net Income | -12.3 M |
| Depreciation & Amortization | 4 K |
| Capital Expenditures | -4 K |
| Stock-Based Compensation | 624 K |
| Change in Working Capital | 400 K |
| Others | 1.03 M |
| Free Cash Flow | -11.1 M |
Wall Street Analysts Price Targets
Palisade Bio, Inc.
PALI has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PALI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Palisade Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
9.67 K USD 2
6-9 MONTHS
16.3 K USD 2
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
7 months ago
May 28, 2024
|
Bought
4.86 K USD
|
Williams Donald Allen
Director
|
+ 1000
|
4.863 USD |
|
7 months ago
May 24, 2024
|
Bought
4.81 K USD
|
Finley John David
CEO, CFO, Director
|
+ 1000
|
4.81 USD |
|
11 months ago
Feb 06, 2024
|
Bought
4.69 K USD
|
Finley John David
CEO, CFO, Director
|
+ 10000
|
0.4692 USD |
|
11 months ago
Jan 31, 2024
|
Bought
5.59 K USD
|
Finley John David
CEO, CFO, Director
|
+ 10000
|
0.559 USD |
|
11 months ago
Jan 31, 2024
|
Bought
6.05 K USD
|
Williams Donald Allen
Director
|
+ 10000
|
0.605 USD |
|
1 year ago
Sep 27, 2023
|
Bought
10.8 K USD
|
Williams Donald Allen
Director
|
+ 20000
|
0.54 USD |
|
1 year ago
Sep 27, 2023
|
Bought
8.09 K USD
|
Finley John David
CEO, CFO, Director
|
+ 15000
|
0.5392 USD |
|
1 year ago
Sep 14, 2023
|
Sell 192
USD
|
Trenschel Robert J.
Director
|
- 300
|
0.64 USD |
|
1 year ago
Sep 13, 2023
|
Bought
9.82 K USD
|
Finley John David
CEO, CFO, Director
|
+ 15000
|
0.655 USD |
|
2 years ago
Sep 01, 2022
|
Bought
2.8 K USD
|
Finley John David
Chief Financial Officer
|
+ 19481.242
|
0.1437 USD |
|
2 years ago
Aug 23, 2022
|
Bought
1.18 K USD
|
Finley John David
Chief Financial Officer
|
+ 7350
|
0.16 USD |
|
2 years ago
Aug 16, 2022
|
Bought
0 USD
|
Hallam Thomas
Chief Executive Officer
|
+ 40000
|
0 USD |
|
2 years ago
Aug 16, 2022
|
Bought
0 USD
|
Finley John David
Chief Financial Officer
|
+ 100000
|
0 USD |
|
2 years ago
Mar 29, 2022
|
Bought
17.1 K USD
|
Dawson Michael John
Chief Medical Officer
|
+ 15000
|
1.1395 USD |
|
2 years ago
Mar 28, 2022
|
Bought
11.8 K USD
|
Hallam Thomas
Chief Executive Officer
|
+ 10000
|
1.18 USD |
|
2 years ago
Mar 24, 2022
|
Bought
8.17 K USD
|
Finley John David
Chief Financial Officer
|
+ 7500
|
1.0899 USD |
|
3 years ago
Sep 21, 2021
|
Bought
4.88 K USD
|
Finley John David
Chief Financial Officer
|
+ 2000
|
2.44 USD |
|
3 years ago
Sep 21, 2021
|
Bought
14.9 K USD
|
Hallam Thomas
Chief Executive Officer
|
+ 6000
|
2.49 USD |
|
3 years ago
Sep 10, 2021
|
Bought
6.38 K USD
|
Trenschel Robert J.
Director
|
+ 2142
|
2.98 USD |
|
3 years ago
Sep 09, 2021
|
Bought
9.83 K USD
|
Trenschel Robert J.
Director
|
+ 3400
|
2.89 USD |
|
3 years ago
Sep 08, 2021
|
Bought
13.8 K USD
|
Trenschel Robert J.
Director
|
+ 5000
|
2.75 USD |
|
3 years ago
Sep 07, 2021
|
Bought
7.53 K USD
|
Trenschel Robert J.
Director
|
+ 2707
|
2.78 USD |
|
3 years ago
Aug 31, 2021
|
Bought
4.81 K USD
|
Trenschel Robert J.
Director
|
+ 1750
|
2.75 USD |
|
3 years ago
Aug 27, 2021
|
Bought
22.3 K USD
|
Finley John David
Chief Financial Officer
|
+ 8400
|
2.65 USD |
|
3 years ago
Aug 27, 2021
|
Bought
4.21 K USD
|
Finley John David
Chief Financial Officer
|
+ 1600
|
2.63 USD |
|
7 years ago
May 17, 2017
|
Bought
30 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 7500
|
4 USD |
|
7 years ago
Mar 24, 2017
|
Bought
30 K USD
|
LLOYD JONES JONATHAN BRIAN
Chief Financial Officer
|
+ 5455
|
5.5 USD |
|
7 years ago
Feb 24, 2017
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 2591
|
3.86 USD |
|
7 years ago
Jan 25, 2017
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 2841
|
3.52 USD |
|
8 years ago
Dec 23, 2016
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 32259
|
0.31 USD |
|
8 years ago
Nov 25, 2016
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 35715
|
0.28 USD |
|
8 years ago
Oct 25, 2016
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 35715
|
0.28 USD |
|
8 years ago
Sep 23, 2016
|
Bought
10 K USD
|
LLOYD JONES JONATHAN BRIAN
Chief Financial Officer
|
+ 31250
|
0.32 USD |
|
8 years ago
Sep 23, 2016
|
Bought
10 K USD
|
Daly Richard J
Chief Executive Officer
|
+ 31250
|
0.32 USD |
|
9 years ago
Nov 16, 2015
|
Sell 27.3 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.09 USD |
|
9 years ago
Nov 09, 2015
|
Sell 29.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.18 USD |
|
9 years ago
Nov 02, 2015
|
Sell 29.4 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.1742 USD |
|
9 years ago
Oct 26, 2015
|
Sell 28.2 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.1276 USD |
|
9 years ago
Oct 19, 2015
|
Sell 30.7 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.2276 USD |
|
9 years ago
Oct 12, 2015
|
Sell 32.7 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.309 USD |
|
9 years ago
Oct 05, 2015
|
Sell 31.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.2584 USD |
|
9 years ago
Sep 28, 2015
|
Sell 41 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.64 USD |
|
9 years ago
Sep 21, 2015
|
Sell 38.1 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 25000
|
1.5231 USD |
|
10 years ago
Sep 02, 2014
|
Sell 24.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
4.09 USD |
|
10 years ago
Aug 01, 2014
|
Sell 16.7 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
2.78 USD |
|
10 years ago
Jul 01, 2014
|
Sell 25 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
4.17 USD |
|
10 years ago
Jun 02, 2014
|
Sell 25.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
4.25 USD |
|
10 years ago
May 05, 2014
|
Bought
49.9 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 14250
|
3.4999 USD |
|
10 years ago
May 05, 2014
|
Bought
3.45 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 985
|
3.5 USD |
|
10 years ago
May 01, 2014
|
Sell 21.3 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
3.5425 USD |
|
10 years ago
Apr 22, 2014
|
Sell 29.8 K
USD
|
GARR RICHARD
CEO
|
- 7000
|
4.25 USD |
|
10 years ago
Apr 01, 2014
|
Sell 24.6 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
4.1063 USD |
|
10 years ago
Mar 20, 2014
|
Sell 24.2 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 6000
|
4.0415 USD |
|
11 years ago
Oct 21, 2013
|
Sell 23.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 10000
|
2.3458 USD |
|
11 years ago
Oct 18, 2013
|
Sell 24.4 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 10000
|
2.4446 USD |
|
11 years ago
Sep 20, 2013
|
Sell 26.2 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 10000
|
2.6241 USD |
|
11 years ago
Sep 19, 2013
|
Sell 26.1 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 10000
|
2.6094 USD |
|
11 years ago
Aug 20, 2013
|
Sell 31 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 20000
|
1.5493 USD |
|
11 years ago
Jul 22, 2013
|
Sell 20.8 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.6234 USD |
|
11 years ago
Jun 20, 2013
|
Sell 17.9 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.395 USD |
|
11 years ago
Jun 07, 2013
|
Sell 8.52 K
USD
|
GARR RICHARD
CEO
|
- 6000
|
1.42 USD |
|
11 years ago
May 20, 2013
|
Sell 19.3 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.5079 USD |
|
11 years ago
Apr 22, 2013
|
Sell 14.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.1344 USD |
|
11 years ago
Mar 20, 2013
|
Sell 14.5 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.1364 USD |
|
11 years ago
Feb 25, 2013
|
Sell 13.8 K
USD
|
GARR RICHARD
CEO
|
- 12000
|
1.15 USD |
|
11 years ago
Feb 20, 2013
|
Sell 15.1 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.18 USD |
|
12 years ago
Jan 22, 2013
|
Sell 16.3 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.27 USD |
|
12 years ago
Dec 20, 2012
|
Sell 14.8 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1.158 USD |
|
12 years ago
Nov 20, 2012
|
Sell 12.8 K
USD
|
JOHE KARL
Chief Scientific Officer
|
- 12800
|
1 USD |
|
14 years ago
Sep 16, 2010
|
Bought
5.78 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 2500
|
2.31 USD |
|
14 years ago
Sep 16, 2010
|
Bought
17.4 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 7500
|
2.32 USD |
|
15 years ago
Dec 30, 2009
|
Bought
312 K USD
|
GARR RICHARD
CEO
|
+ 189111
|
1.65 USD |
|
15 years ago
Dec 30, 2009
|
Bought
60 K USD
|
CONRON JOHN
Chief Financial Officer
|
+ 36364
|
1.65 USD |
|
16 years ago
Aug 21, 2008
|
Bought
3.89 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 2200
|
1.77 USD |
|
16 years ago
Aug 21, 2008
|
Bought
5.37 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 3000
|
1.79 USD |
|
16 years ago
Aug 21, 2008
|
Bought
910 USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 500
|
1.82 USD |
|
16 years ago
Aug 21, 2008
|
Bought
2.74 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 1500
|
1.83 USD |
|
16 years ago
Aug 21, 2008
|
Bought
5.61 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 3000
|
1.87 USD |
|
16 years ago
Aug 21, 2008
|
Bought
3.89 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 2200
|
1.77 USD |
|
16 years ago
Aug 21, 2008
|
Bought
5.37 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 3000
|
1.79 USD |
|
16 years ago
Aug 21, 2008
|
Bought
910 USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 500
|
1.82 USD |
|
16 years ago
Aug 21, 2008
|
Bought
2.74 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 1500
|
1.83 USD |
|
16 years ago
Aug 21, 2008
|
Bought
5.61 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 3000
|
1.87 USD |
|
16 years ago
Jul 10, 2008
|
Bought
2.48 K USD
|
CONRON JOHN
Chief Financial Officer
|
+ 1700
|
1.46 USD |
|
16 years ago
Jul 10, 2008
|
Bought
715 USD
|
CONRON JOHN
Chief Financial Officer
|
+ 500
|
1.43 USD |
|
16 years ago
Jul 10, 2008
|
Bought
846 USD
|
CONRON JOHN
Chief Financial Officer
|
+ 600
|
1.41 USD |
|
16 years ago
Jul 10, 2008
|
Bought
875 USD
|
CONRON JOHN
Chief Financial Officer
|
+ 625
|
1.4 USD |
|
16 years ago
Jul 10, 2008
|
Bought
1.36 K USD
|
CONRON JOHN
Chief Financial Officer
|
+ 1000
|
1.36 USD |
|
16 years ago
Jul 10, 2008
|
Bought
135 USD
|
CONRON JOHN
Chief Financial Officer
|
+ 100
|
1.35 USD |
|
16 years ago
Jul 10, 2008
|
Bought
627 USD
|
CONRON JOHN
Chief Financial Officer
|
+ 475
|
1.32 USD |
|
16 years ago
Jul 07, 2008
|
Bought
69.6 K USD
|
GARR RICHARD
CEO, President
|
+ 49000
|
1.42 USD |
|
16 years ago
Jun 03, 2008
|
Bought
19.5 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 10000
|
1.95 USD |
|
16 years ago
May 30, 2008
|
Bought
16 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 10000
|
1.6 USD |
|
16 years ago
Feb 08, 2008
|
Bought
29.2 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 9700
|
3.0128 USD |
|
17 years ago
Sep 19, 2007
|
Bought
22.5 K USD
|
OLDAKER WILLIAM CLYDE
Director
|
+ 7500
|
2.997 USD |
|
17 years ago
Apr 17, 2007
|
Bought
35 K USD
|
CONRON JOHN
Chief Financial Officer
|
+ 10000
|
3.5 USD |
7. News
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended.
globenewswire.com
- 2 weeks ago
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.
globenewswire.com
- 1 month ago
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).
globenewswire.com
- 1 month ago
What's Going On With Palisade Bio Stock On Thursday?
On Thursday, Palisade Bio Inc PALI stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.
benzinga.com
- 1 month ago
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).
globenewswire.com
- 1 month ago
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for PALI-2108 for the treatment of Ulcerative Colitis (UC). The ongoing Phase 1 study is evaluating PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers, alongside an open-label study involving a patient cohort with UC.
globenewswire.com
- 1 month ago
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Data to be presented at the 8 th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its potential as an effective treatment for fibrostenotic Crohn's disease.
globenewswire.com
- 1 month ago
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)
globenewswire.com
- 2 months ago
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).
globenewswire.com
- 2 months ago
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)
globenewswire.com
- 3 months ago
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end
globenewswire.com
- 5 months ago
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end
globenewswire.com
- 5 months ago
8. Profile
Summary
Palisade Bio, Inc. PALI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.09 M
Dividend Yield
0.00%
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Contact
5800 Armada Drive, Carlsbad, CA, 92008
https://www.palisadebio.com
IPO
Date
March 30, 2007
Employees
9
Officers
Mr. Ryker Willie
Senior Vice President of Finance & Corporate Controller
Mr. J. D. Finley
Chief Executive Officer, Chief Financial Officer & Director
Dr. Joerg Heyer Ph.D.
Head of Translational Science & Medicine
Dr. Mitchell Lawrence Jones M.D., Ph.D.
Chief Operating Officer & Chief Medical Officer